Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 24.60
- Piotroski Score 4.00
- Grade Buy
- Symbol (RNA)
- Company Avidity Biosciences, Inc.
- Price $44.60
- Changes Percentage (-0.49%)
- Change -$0.22
- Day Low $44.02
- Day High $45.43
- Year High $50.78
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; AOC 1044 for the treatment of Duchenne Muscular Dystrophy; and AOC 1020 designed to treat facioscapulohumeral muscular dystrophy which are in preclinical stage. It also offers Lumizyme therapy for Pompe diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/06/2024
- Fiscal Year End N/A
- Average Stock Price Target $54.50
- High Stock Price Target $59.00
- Low Stock Price Target $50.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$2.96
- Trailing P/E Ratio -8.99
- Forward P/E Ratio -8.99
- P/E Growth -8.99
- Net Income $-212,220,000
Income Statement
Quarterly
Annual
Latest News of RNA
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
When Will We Find Out Who the Next President Is? Steve Kornacki Tells PEOPLE It Won't Be Like 2020
Lizzie Hyman works as an Editorial Assistant at PEOPLE Magazine, assisting the Editor-in-Chief and contributing content for print and digital platforms....
By PEOPLE.com | 5 hours ago -
MGM Resorts International (MGM) Yet Again Delivers Record Revenue in Q3
The global gambling market is projected to grow, influenced by factors like legalization, urbanization, and sports betting. The industry is evolving, with Las Vegas seeing a resurgence post-pandemic. ...
By Yahoo! Finance | 6 hours ago -
Verona Pharma PLC (VRNA) Q3 2024 Earnings Call Highlights: Strong Ohtuvayre Launch Amid Rising Costs
Over 5,000 unique patients have been prescribed Ohtuvayre, with increasing refills and patient adds. Prescriber trends show a broad range of therapy combinations. Infrastructure for patient access is ...
By Yahoo! Finance | 7 hours ago
